Sign In
About ASHM | Careers | Your Cart Shoppint Cart
Skip Navigation LinksASHM Internet Home > Resources

Resources

​​​Monitoring hepatitis C treatment uptake in Australia

Kirkby Institute - Monitoring HCV.JPGThis is a monthly newsletter available as a PDF download from the Viral Hepatitis Clinical Research Program – a rapidly expanding area of clinical research and development within the Kirby Institute. The program focuses on therapeutic research in viral hepatitis – clinical research (including clinical trials forms the main part of the program’s work); the recently established viral hepatitis sample repository, HepBank, for molecular virology research; and epidemiological research through data linkage studies and mathematical modelling.

This report summarises data on prescribing to date and provides a great insight into the initial phase of the roll-out of DAA therapy in Australia. 


Australian recommendations for the management of hepatitis C virus infection: Consensus statement 2017

Webpart Spotlight - HCV Consensus Statement Google.jpgDownload here:  Australian recommendations for the management of Hepatitis C virus infection: a consensus statement January 2017 (PDF, 875Kb).

This was prepared by an expert panel representing the Gastroenterological Society of Australia (Australian Liver Association), the Australasian Society for Infectious Diseases, the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine, the Australasian Hepa tology Association, Hepatitis Australia and the Royal Australian College of General Practitioners.


It is intended to be used as a reference for health professionals involved in the management and treatment of hepatitis C.

Also visit the HCV Consensus Statement website at www.hepcguidelines.org.au. Alternatively, download the app (suitable for all mobile devices) from Google Play and Apple iTunes store.


Hepatitis B and C in Australia Annual Surveillance Report Supplement 2016

2016_Kirby_Surveillance_100px.jpgThis Hepatitis B and C in Australia Annual Surveillance Report Supplement 2016 published by The Kirby Institute for infection and immunity in society provides an overview of trends in diagnoses, prevalence, incidence, morbidity, care, testing and prevention of hepatitis B and C viral infections.

Download the PDF



Annual Report of Trends in Behaviour Supplement 2016 on viral hepatitis

ARTB_Viral_Hep_Cover_100px.jpgThe Annual Report of Trends in Behaviour presents data from a selection of the behavioural and social research conducted by the Centre for Social Research in Health. The report focuses in particular on studies assessing trends over time or addressing emerging issues.

Download the PDF


Browse



Clear filters

 

 

Australian recommendations for the management of hepatitis C virus infection: Consensus statement 2016http://www.ashm.org.au/resources/Pages/01032016.aspxAustralian recommendations for the management of hepatitis C virus infection: Consensus statement 2016Prepared by an expert panel, this document provides guidance on epidemiology, models of care, diagnosis, pre-treatment assessment, monitoring and treatment.GP0|#dcb5bb65-47fe-4de8-bef4-63504a92e3d3;L0|#0dcb5bb65-47fe-4de8-bef4-63504a92e3d3|Booklet;GTSet|#48fc36ff-f241-4a97-8906-dc332a2c106e;GPP|#a700ed02-fbb9-4529-9868-7e249cd119ecGP0|#a1581b02-cca1-478b-9d26-5045f1b59502;L0|#0a1581b02-cca1-478b-9d26-5045f1b59502|Hepatitis C;GTSet|#dd3bb5ec-7f07-44a6-ad6a-353b82624b89GP0|#43e42eb1-a069-43e4-baff-1bc89aeaeb11;L0|#043e42eb1-a069-43e4-baff-1bc89aeaeb11|ASHM;GTSet|#e2da4fc3-3bee-4dbc-83a4-35cc0aae5aa428/02/2016 1:00:00 PM
HCV New Treatments Quick Reference Toolhttp://www.ashm.org.au/resources/Pages/978-1-920773-46-5.aspxHCV New Treatments Quick Reference ToolThis two-page quick reference guide assists health professionals to decide which new direct acting antiviral hepatitis C treatment regimen is most appropriate for their patient. GP0|#9ac742b4-1677-49fd-9f7a-c0e73d2957b5;L0|#09ac742b4-1677-49fd-9f7a-c0e73d2957b5|Decision Making Tool;GTSet|#48fc36ff-f241-4a97-8906-dc332a2c106e;GPP|#a700ed02-fbb9-4529-9868-7e249cd119ecGP0|#f001df20-76bd-422b-9adc-dc3407467c1e;L0|#0f001df20-76bd-422b-9adc-dc3407467c1e|Co-infection;GTSet|#dd3bb5ec-7f07-44a6-ad6a-353b82624b89;GP0|#a1581b02-cca1-478b-9d26-5045f1b59502;L0|#0a1581b02-cca1-478b-9d26-5045f1b59502|Hepatitis C;GP0|#76668c93-9a35-43ee-918b-a18a40ef5c30;L0|#076668c93-9a35-43ee-918b-a18a40ef5c30|Liver CancerGP0|#43e42eb1-a069-43e4-baff-1bc89aeaeb11;L0|#043e42eb1-a069-43e4-baff-1bc89aeaeb11|ASHM;GTSet|#e2da4fc3-3bee-4dbc-83a4-35cc0aae5aa424/07/2016 4:00:00 AM
Primary Care Providers and Hepatitis Chttp://www.ashm.org.au/resources/Pages/978-1-920773-42-7.aspxPrimary Care Providers and Hepatitis CThis booklet for Primary Care Providers includes information on the hepatitis C virus, the natural history of HCV, a straightforward 12 step plan for the management of HCV and treatment protocols with the new direct acting antiviral (DAAs) medications.GP0|#dcb5bb65-47fe-4de8-bef4-63504a92e3d3;L0|#0dcb5bb65-47fe-4de8-bef4-63504a92e3d3|Booklet;GTSet|#48fc36ff-f241-4a97-8906-dc332a2c106e;GPP|#a700ed02-fbb9-4529-9868-7e249cd119ecGP0|#f001df20-76bd-422b-9adc-dc3407467c1e;L0|#0f001df20-76bd-422b-9adc-dc3407467c1e|Co-infection;GTSet|#dd3bb5ec-7f07-44a6-ad6a-353b82624b89;GP0|#a1581b02-cca1-478b-9d26-5045f1b59502;L0|#0a1581b02-cca1-478b-9d26-5045f1b59502|Hepatitis CGP0|#43e42eb1-a069-43e4-baff-1bc89aeaeb11;L0|#043e42eb1-a069-43e4-baff-1bc89aeaeb11|ASHM;GTSet|#e2da4fc3-3bee-4dbc-83a4-35cc0aae5aa422/06/2016 4:00:00 AM
HIV, Viral Hepatitis, STIs: A Guide for Primary Care Providers (4th Edition)http://www.ashm.org.au/resources/Pages/1976963411.aspxHIV, Viral Hepatitis, STIs: A Guide for Primary Care Providers (4th Edition)This monograph is a leading HIV, viral hepatitis and STI clinical resource, reflecting current knowledge and recommended practice in primary care settings.GP0|#eca81a01-0ba2-4e98-8935-5523ff706f40;L0|#0eca81a01-0ba2-4e98-8935-5523ff706f40|Monograph;GTSet|#48fc36ff-f241-4a97-8906-dc332a2c106e;GPP|#a700ed02-fbb9-4529-9868-7e249cd119ecGP0|#8ab7205f-9a3e-4243-b625-fa0c0db6a04c;L0|#08ab7205f-9a3e-4243-b625-fa0c0db6a04c|Hepatitis B;GTSet|#dd3bb5ec-7f07-44a6-ad6a-353b82624b89;GP0|#a1581b02-cca1-478b-9d26-5045f1b59502;L0|#0a1581b02-cca1-478b-9d26-5045f1b59502|Hepatitis C;GP0|#dd9963c0-8c72-40e7-83e9-94fb06eb72f5;L0|#0dd9963c0-8c72-40e7-83e9-94fb06eb72f5|HIV;GP0|#66dd8656-12a3-4d79-958c-88d53f70255d;L0|#066dd8656-12a3-4d79-958c-88d53f70255d|STIGP0|#43e42eb1-a069-43e4-baff-1bc89aeaeb11;L0|#043e42eb1-a069-43e4-baff-1bc89aeaeb11|ASHM;GTSet|#e2da4fc3-3bee-4dbc-83a4-35cc0aae5aa431/08/2014 4:00:00 AM
Decision-Making in HCVhttp://www.ashm.org.au/resources/Pages/978-1-920773-43-4.aspxDecision-Making in HCVThis decision-making guide will assist primary care clinicians in the assessment, management and treatment of hepatitis C. GP0|#9ac742b4-1677-49fd-9f7a-c0e73d2957b5;L0|#09ac742b4-1677-49fd-9f7a-c0e73d2957b5|Decision Making Tool;GTSet|#48fc36ff-f241-4a97-8906-dc332a2c106e;GPP|#a700ed02-fbb9-4529-9868-7e249cd119ecGP0|#f001df20-76bd-422b-9adc-dc3407467c1e;L0|#0f001df20-76bd-422b-9adc-dc3407467c1e|Co-infection;GTSet|#dd3bb5ec-7f07-44a6-ad6a-353b82624b89;GP0|#a1581b02-cca1-478b-9d26-5045f1b59502;L0|#0a1581b02-cca1-478b-9d26-5045f1b59502|Hepatitis C;GP0|#76668c93-9a35-43ee-918b-a18a40ef5c30;L0|#076668c93-9a35-43ee-918b-a18a40ef5c30|Liver CancerGP0|#43e42eb1-a069-43e4-baff-1bc89aeaeb11;L0|#043e42eb1-a069-43e4-baff-1bc89aeaeb11|ASHM;GTSet|#e2da4fc3-3bee-4dbc-83a4-35cc0aae5aa421/08/2016 4:00:00 AM
Nurses and Hepatitis C 2016http://www.ashm.org.au/resources/Pages/978-1-920773-44-1.aspxNurses and Hepatitis C 2016This updated 8 page booklet is targetted at nurses who manage and care for people living with, and affected by, hepatitis C.GP0|#dcb5bb65-47fe-4de8-bef4-63504a92e3d3;L0|#0dcb5bb65-47fe-4de8-bef4-63504a92e3d3|Booklet;GTSet|#48fc36ff-f241-4a97-8906-dc332a2c106e;GPP|#a700ed02-fbb9-4529-9868-7e249cd119ecGP0|#f001df20-76bd-422b-9adc-dc3407467c1e;L0|#0f001df20-76bd-422b-9adc-dc3407467c1e|Co-infection;GTSet|#dd3bb5ec-7f07-44a6-ad6a-353b82624b89;GP0|#a1581b02-cca1-478b-9d26-5045f1b59502;L0|#0a1581b02-cca1-478b-9d26-5045f1b59502|Hepatitis C;GP0|#76668c93-9a35-43ee-918b-a18a40ef5c30;L0|#076668c93-9a35-43ee-918b-a18a40ef5c30|Liver CancerGP0|#43e42eb1-a069-43e4-baff-1bc89aeaeb11;L0|#043e42eb1-a069-43e4-baff-1bc89aeaeb11|ASHM;GTSet|#e2da4fc3-3bee-4dbc-83a4-35cc0aae5aa420/07/2016 4:00:00 AM
Police and Blood-Borne Viruses 2015http://www.ashm.org.au/resources/Pages/978-1-920773-39-7.aspxPolice and Blood-Borne Viruses 2015This eight page booklet about blood-borne viruses is targetted at Police Officers across Australia.GP0|#dcb5bb65-47fe-4de8-bef4-63504a92e3d3;L0|#0dcb5bb65-47fe-4de8-bef4-63504a92e3d3|Booklet;GTSet|#48fc36ff-f241-4a97-8906-dc332a2c106e;GPP|#a700ed02-fbb9-4529-9868-7e249cd119ecGP0|#f001df20-76bd-422b-9adc-dc3407467c1e;L0|#0f001df20-76bd-422b-9adc-dc3407467c1e|Co-infection;GTSet|#dd3bb5ec-7f07-44a6-ad6a-353b82624b89;GP0|#8ab7205f-9a3e-4243-b625-fa0c0db6a04c;L0|#08ab7205f-9a3e-4243-b625-fa0c0db6a04c|Hepatitis B;GP0|#a1581b02-cca1-478b-9d26-5045f1b59502;L0|#0a1581b02-cca1-478b-9d26-5045f1b59502|Hepatitis C;GP0|#dd9963c0-8c72-40e7-83e9-94fb06eb72f5;L0|#0dd9963c0-8c72-40e7-83e9-94fb06eb72f5|HIV;GP0|#66dd8656-12a3-4d79-958c-88d53f70255d;L0|#066dd8656-12a3-4d79-958c-88d53f70255d|STIGP0|#43e42eb1-a069-43e4-baff-1bc89aeaeb11;L0|#043e42eb1-a069-43e4-baff-1bc89aeaeb11|ASHM;GTSet|#e2da4fc3-3bee-4dbc-83a4-35cc0aae5aa423/06/2015 2:00:00 PM
Stigma and Discrimination around HIV and HCV in Healthcare Settings: Research Reporthttp://www.ashm.org.au/resources/Pages/1976963391.aspxStigma and Discrimination around HIV and HCV in Healthcare Settings: Research ReportTaking a comprehensive look stigma and discrimination in the health care sector, this report focuses on the experiences of people living with HIV and/or hepatitis CGP0|#dcb5bb65-47fe-4de8-bef4-63504a92e3d3;L0|#0dcb5bb65-47fe-4de8-bef4-63504a92e3d3|Booklet;GTSet|#48fc36ff-f241-4a97-8906-dc332a2c106e;GPP|#a700ed02-fbb9-4529-9868-7e249cd119ecGP0|#dd9963c0-8c72-40e7-83e9-94fb06eb72f5;L0|#0dd9963c0-8c72-40e7-83e9-94fb06eb72f5|HIV;GTSet|#dd3bb5ec-7f07-44a6-ad6a-353b82624b89;GP0|#a1581b02-cca1-478b-9d26-5045f1b59502;L0|#0a1581b02-cca1-478b-9d26-5045f1b59502|Hepatitis CGP0|#43e42eb1-a069-43e4-baff-1bc89aeaeb11;L0|#043e42eb1-a069-43e4-baff-1bc89aeaeb11|ASHM;GTSet|#e2da4fc3-3bee-4dbc-83a4-35cc0aae5aa431/12/2012 2:00:00 AM
Decision Making in Viral Hepatitis Related Advanced Liver Diseasehttp://www.ashm.org.au/resources/Pages/978-1-920773-41-0.aspxDecision Making in Viral Hepatitis Related Advanced Liver DiseaseThis two-page quick reference guide assists health professionals to evaluate patients for viral hepatitis related advanced liver disease and provides an overview of the management of compensated and decompensated cirrhosis. GP0|#9ac742b4-1677-49fd-9f7a-c0e73d2957b5;L0|#09ac742b4-1677-49fd-9f7a-c0e73d2957b5|Decision Making Tool;GTSet|#48fc36ff-f241-4a97-8906-dc332a2c106e;GPP|#a700ed02-fbb9-4529-9868-7e249cd119ecGP0|#f001df20-76bd-422b-9adc-dc3407467c1e;L0|#0f001df20-76bd-422b-9adc-dc3407467c1e|Co-infection;GTSet|#dd3bb5ec-7f07-44a6-ad6a-353b82624b89;GP0|#8ab7205f-9a3e-4243-b625-fa0c0db6a04c;L0|#08ab7205f-9a3e-4243-b625-fa0c0db6a04c|Hepatitis B;GP0|#a1581b02-cca1-478b-9d26-5045f1b59502;L0|#0a1581b02-cca1-478b-9d26-5045f1b59502|Hepatitis C;GP0|#76668c93-9a35-43ee-918b-a18a40ef5c30;L0|#076668c93-9a35-43ee-918b-a18a40ef5c30|Liver CancerGP0|#43e42eb1-a069-43e4-baff-1bc89aeaeb11;L0|#043e42eb1-a069-43e4-baff-1bc89aeaeb11|ASHM;GTSet|#e2da4fc3-3bee-4dbc-83a4-35cc0aae5aa424/02/2016 2:00:00 AM
Antenatal Testing and Blood-Borne Viruses (BBVs) 2015http://www.ashm.org.au/resources/Pages/978-1-920773-97-5 (2015).aspxAntenatal Testing and Blood-Borne Viruses (BBVs) 2015This updated resource is for health professionals providing women with antenatal care.GP0|#dcb5bb65-47fe-4de8-bef4-63504a92e3d3;L0|#0dcb5bb65-47fe-4de8-bef4-63504a92e3d3|Booklet;GTSet|#48fc36ff-f241-4a97-8906-dc332a2c106e;GPP|#a700ed02-fbb9-4529-9868-7e249cd119ecGP0|#f001df20-76bd-422b-9adc-dc3407467c1e;L0|#0f001df20-76bd-422b-9adc-dc3407467c1e|Co-infection;GTSet|#dd3bb5ec-7f07-44a6-ad6a-353b82624b89;GP0|#8ab7205f-9a3e-4243-b625-fa0c0db6a04c;L0|#08ab7205f-9a3e-4243-b625-fa0c0db6a04c|Hepatitis B;GP0|#a1581b02-cca1-478b-9d26-5045f1b59502;L0|#0a1581b02-cca1-478b-9d26-5045f1b59502|Hepatitis C;GP0|#dd9963c0-8c72-40e7-83e9-94fb06eb72f5;L0|#0dd9963c0-8c72-40e7-83e9-94fb06eb72f5|HIV;GP0|#66dd8656-12a3-4d79-958c-88d53f70255d;L0|#066dd8656-12a3-4d79-958c-88d53f70255d|STIGP0|#43e42eb1-a069-43e4-baff-1bc89aeaeb11;L0|#043e42eb1-a069-43e4-baff-1bc89aeaeb11|ASHM;GTSet|#e2da4fc3-3bee-4dbc-83a4-35cc0aae5aa419/04/2015 4:00:00 AM

Please enter a valid E-mail.
This must match your colleagues E-mail.
Please enter your name.
Please enter a valid email.
This must match your email.